BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25264279)

  • 21. [Prolonged mivacurium induced neuromuscular block in 5 patients homozygotic for atypical butyrylcholinesterase phenotype].
    Burnat P; Soulard D; Jacquel A; Coste T; Le Marchand P; Benoist JF
    Ann Fr Anesth Reanim; 1995; 14(6):532. PubMed ID: 8745981
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of neuromuscular monitoring to detect prolonged effect of succinylcholine or mivacurium: three case reports.
    Cassel J; Staehr-Rye AK; Nielsen CV; Gätke MR
    Acta Anaesthesiol Scand; 2014 Sep; 58(8):1040-3. PubMed ID: 24947746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prolonged neuromuscular block in a patient with butyrylcholinesterase deficiency].
    Mabboux I; Hary B; Courcelle S; Ceppa F; Delacour H
    Arch Pediatr; 2016 May; 23(5):497-500. PubMed ID: 27017361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudocholinesterase-mediated hydrolysis is superior to neostigmine for reversal of mivacurium-induced paralysis in vitro.
    Yang HS; Goudsouzian N; Martyn JA
    Anesthesiology; 1996 Apr; 84(4):936-44. PubMed ID: 8638849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel mutation in the BCHE gene and phenotype identified in a child with low butyrylcholinesterase activity: a case report.
    Yu R; Guo Y; Dan Y; Tan W; Mao Q; Deng G
    BMC Med Genet; 2018 Apr; 19(1):58. PubMed ID: 29631548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computer-designed active human butyrylcholinesterase double mutant with a new catalytic triad.
    Grigorenko BL; Novichkova DA; Lushchekina SV; Zueva IV; Schopfer LM; Nemukhin AV; Varfolomeev SD; Lockridge O; Masson P
    Chem Biol Interact; 2019 Jun; 306():138-146. PubMed ID: 31009643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substrate selectivity of high-activity mutants of human butyrylcholinesterase.
    Hou S; Xue L; Yang W; Fang L; Zheng F; Zhan CG
    Org Biomol Chem; 2013 Nov; 11(43):7477-85. PubMed ID: 24077614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuromuscular effects of mivacurium in 2- to 12-yr-old children with burn injury.
    Martyn JA; Goudsouzian NG; Chang Y; Szyfelbein SK; Schwartz AE; Patel SS
    Anesthesiology; 2000 Jan; 92(1):31-7. PubMed ID: 10638896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prolonged neuromuscular block after administration of mivacurium caused by plasma psueudocholinesterase deficiency].
    Kaiser E; Petit D; Quinot JF; Suppini A; Sallaberry M
    Ann Fr Anesth Reanim; 1995; 14(6):505-7. PubMed ID: 8745975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cholinesterases].
    Lejus C; Blanloeil Y; Burnat P; Souron R
    Ann Fr Anesth Reanim; 1998; 17(9):1122-35. PubMed ID: 9835982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.
    Frampton JE; McTavish D
    Drugs; 1993 Jun; 45(6):1066-1089. PubMed ID: 7691494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyol-induced activation by excess substrate of the D70G butyrylcholinesterase mutant.
    Levitsky V; Xie W; Froment MT; Lockridge O; Masson P
    Biochim Biophys Acta; 1999 Jan; 1429(2):422-30. PubMed ID: 9989227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine.
    Levano S; Ginz H; Siegemund M; Filipovic M; Voronkov E; Urwyler A; Girard T
    Anesthesiology; 2005 Mar; 102(3):531-5. PubMed ID: 15731589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anionic site interactions in human butyrylcholinesterase disrupted by two single point mutations.
    Neville LF; Gnatt A; Padan R; Seidman S; Soreq H
    J Biol Chem; 1990 Dec; 265(34):20735-8. PubMed ID: 2249982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mivacurium-induced prolonged neuromuscular block.
    Sockalingam I; Green DW
    Br J Anaesth; 1995 Feb; 74(2):234-6. PubMed ID: 7696076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naturally occurring mutation, Asp70his, in human butyrylcholinesterase.
    Boeck AT; Fry DL; Sastre A; Lockridge O
    Ann Clin Biochem; 2002 Mar; 39(Pt 2):154-6. PubMed ID: 11928765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid identification of atypical variant of plasma butyrylcholinesterase by PCR.
    Ceppa F; Gidenne S; Benois A; Fontan E; Burnat P
    Clin Chem Lab Med; 2002 Aug; 40(8):799-801. PubMed ID: 12392308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Indian butyrylcholinesterase variant L307P is not structurally stable: a molecular dynamics simulation study.
    David SM; Venkatesan SK; Boopathy R
    Chem Biol Interact; 2013 Mar; 203(1):30-5. PubMed ID: 23123771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased plasma cholinesterase activity and mivacurium resistance: report of a family.
    Naguib M; Gomaa M; Samarkandi AH; Bevan DR; Akkielah AK; Watson C; Billecke S; La Du BN
    Anesth Analg; 1999 Dec; 89(6):1579-82. PubMed ID: 10589654
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of succinylcholine on the recovery of block produced by mivacurium in rats.
    Kanyamibwa D; Tsaousi G; Karakoulas K; Thomareis O; Parlapani A; Makedou AH; Giala M
    Methods Find Exp Clin Pharmacol; 2008 Apr; 30(3):187-91. PubMed ID: 18597002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.